Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional RadiologyHINGHAM, Mass., July 11, 2023 Microbot Medical.
Ascelia Pharma recently presented data from its Orviglance Hepatic Impairment study showing that Orviglance, a non-gadolinium oral contrast agent, has the potential to be used in patients with any degree of liver impairment. The data was presented during the June 14-16 European Society of Gastrointestinal and Abdominal Radiology (ESGAR), held in Valencia, Spain.